Rebekah J Nevel1, Errine T Garnett2, Deneen A Schaudies1, Lisa R Young1,2. 1. Division of Pulmonary Medicine, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee. 2. Division of Allergy, Pulmonary and Critical Care, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.
Abstract
RATIONALE: Neuroendocrine cell hyperplasia of infancy (NEHI) typically presents in infancy with tachypnea, retractions, and hypoxemia. Some infants have failure to thrive, yet the frequency of this and other non-respiratory phenotypic features have not been delineated. While gradual improvement occurs, the clinical course is variable and the duration of supplemental oxygen requirement has not been defined. OBJECTIVES: Our objective was to identify factors in NEHI that may drive differences in clinical course. We hypothesized that failure to thrive would be associated with greater duration of supplemental oxygen use. METHODS: Children with NEHI were identified as a nested retrospective cohort within an ongoing observational prospective study. An electronic questionnaire evaluating health status was distributed to the parents/guardians. Clinical data were obtained via chart review and parent interview. RESULTS: Of 42 children, 74% had a diagnosis of failure to thrive during their clinical course. Time to event analysis demonstrated that 50% discontinued daytime and nighttime oxygen at 32 and 87.5 months after initiation, respectively. Diagnosis of failure to thrive was associated with longer continuous oxygen supplementation, P = 0.03. Additional parental concerns identified through the electronic questionnaire included developmental delays, multiple hospitalizations, and delays in diagnosis. CONCLUSIONS: NEHI is associated with substantial respiratory and extra-pulmonary morbidity. Failure to thrive may be associated with greater respiratory morbidity, though further studies are required to define this interaction. Determining the association of these comorbidities and respiratory course in NEHI may enable development of strategies to improve these modifiable factors and potentially pulmonary outcomes.
RATIONALE: Neuroendocrine cell hyperplasia of infancy (NEHI) typically presents in infancy with tachypnea, retractions, and hypoxemia. Some infants have failure to thrive, yet the frequency of this and other non-respiratory phenotypic features have not been delineated. While gradual improvement occurs, the clinical course is variable and the duration of supplemental oxygen requirement has not been defined. OBJECTIVES: Our objective was to identify factors in NEHI that may drive differences in clinical course. We hypothesized that failure to thrive would be associated with greater duration of supplemental oxygen use. METHODS:Children with NEHI were identified as a nested retrospective cohort within an ongoing observational prospective study. An electronic questionnaire evaluating health status was distributed to the parents/guardians. Clinical data were obtained via chart review and parent interview. RESULTS: Of 42 children, 74% had a diagnosis of failure to thrive during their clinical course. Time to event analysis demonstrated that 50% discontinued daytime and nighttime oxygen at 32 and 87.5 months after initiation, respectively. Diagnosis of failure to thrive was associated with longer continuous oxygen supplementation, P = 0.03. Additional parental concerns identified through the electronic questionnaire included developmental delays, multiple hospitalizations, and delays in diagnosis. CONCLUSIONS: NEHI is associated with substantial respiratory and extra-pulmonary morbidity. Failure to thrive may be associated with greater respiratory morbidity, though further studies are required to define this interaction. Determining the association of these comorbidities and respiratory course in NEHI may enable development of strategies to improve these modifiable factors and potentially pulmonary outcomes.
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: Heikki Lukkarinen; Anna Pelkonen; Jouko Lohi; Kristiina Malmström; L Pekka Malmberg; Merja Kajosaari; Harri Lindahl; Anna Föhr; Olli Ruuskanen; Mika J Mäkelä Journal: Arch Dis Child Date: 2012-11-17 Impact factor: 3.791
Authors: Andrew Bush; Steve Cunningham; Jacques de Blic; Angelo Barbato; Annick Clement; Ralph Epaud; Meike Hengst; Nural Kiper; Andrew G Nicholson; Martin Wetzke; Deborah Snijders; Nicolaus Schwerk; Matthias Griese Journal: Thorax Date: 2015-07-01 Impact factor: 9.139
Authors: Jan L Wallander; Carla M Bann; Fred J Biasini; Shivaprasad S Goudar; Omrana Pasha; Elwyn Chomba; Elizabeth McClure; Waldemar A Carlo Journal: J Child Psychol Psychiatry Date: 2014-05-09 Impact factor: 8.982
Authors: Don B Sanders; Aliza Fink; Nicole Mayer-Hamblett; Michael S Schechter; Gregory S Sawicki; Margaret Rosenfeld; Patrick A Flume; Wayne J Morgan Journal: J Pediatr Date: 2015-09-02 Impact factor: 4.406
Authors: Deborah R Liptzin; Kaci Pickett; John T Brinton; Amit Agarwal; Martha P Fishman; Alicia Casey; Christopher T Towe; Jane B Taylor; Geoffrey Kurland; James S Hagood; Jennifer Wambach; Ruma Srivastava; Hani Al-Saleh; Sharon D Dell; Lisa R Young; Robin R Deterding Journal: Ann Am Thorac Soc Date: 2020-06
Authors: Jinhao Xu; Le Xu; Pengfei Sui; Jiyuan Chen; Esteban A Moya; Patrick Hume; William J Janssen; Jason M Duran; Patricia Thistlethwaite; Aaron Carlin; Peter Gulleman; Brandon Banaschewski; Mary Kate Goldy; Jason X-J Yuan; Atul Malhotra; Gloria Pryhuber; Laura Crotty-Alexander; Gail Deutsch; Lisa R Young; Xin Sun Journal: Dev Cell Date: 2022-03-17 Impact factor: 13.417
Authors: Don Hayes; Kevin C Wilson; Katelyn Krivchenia; Stephen M M Hawkins; Ian M Balfour-Lynn; David Gozal; Howard B Panitch; Mark L Splaingard; Lawrence M Rhein; Geoffrey Kurland; Steven H Abman; Timothy M Hoffman; Christopher L Carroll; Mary E Cataletto; Dmitry Tumin; Eyal Oren; Richard J Martin; Joyce Baker; Gregory R Porta; Deborah Kaley; Ann Gettys; Robin R Deterding Journal: Am J Respir Crit Care Med Date: 2019-02-01 Impact factor: 21.405